QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)

Morphic (MORF) Competitors

$38.16
+2.51 (+7.04%)
(As of 02/27/2024 ET)

MORF vs. ALPN, AMRX, KROS, NAMS, ZLAB, HRMY, SNDX, CPRX, PTCT, and DVAX

Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Alpine Immune Sciences (ALPN), Amneal Pharmaceuticals (AMRX), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), Zai Lab (ZLAB), Harmony Biosciences (HRMY), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), PTC Therapeutics (PTCT), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.

Morphic vs.

Alpine Immune Sciences (NASDAQ:ALPN) and Morphic (NASDAQ:MORF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.

75.2% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 80.7% of Morphic shares are owned by institutional investors. 42.3% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 28.1% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alpine Immune Sciences received 296 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 65.16% of users gave Alpine Immune Sciences an outperform vote while only 59.54% of users gave Morphic an outperform vote.

CompanyUnderperformOutperform
Alpine Immune SciencesOutperform Votes
374
65.16%
Underperform Votes
200
34.84%
MorphicOutperform Votes
78
59.54%
Underperform Votes
53
40.46%

Morphic has a net margin of 0.00% compared to Morphic's net margin of -185.10%. Alpine Immune Sciences' return on equity of -23.62% beat Morphic's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpine Immune Sciences-185.10% -33.53% -21.88%
Morphic N/A -23.62%-22.90%

Alpine Immune Sciences has higher revenue and earnings than Morphic. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Morphic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpine Immune Sciences$30.06M69.50-$57.76M-$1.20-29.97
Morphic$521K3,664.90-$152.10M-$3.49-10.93

In the previous week, Morphic had 7 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 10 mentions for Morphic and 3 mentions for Alpine Immune Sciences. Morphic's average media sentiment score of 1.05 beat Alpine Immune Sciences' score of 0.80 indicating that Alpine Immune Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpine Immune Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Morphic
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alpine Immune Sciences has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Alpine Immune Sciences currently has a consensus target price of $29.00, suggesting a potential downside of 19.35%. Morphic has a consensus target price of $59.75, suggesting a potential upside of 56.58%. Given Alpine Immune Sciences' higher probable upside, analysts clearly believe Morphic is more favorable than Alpine Immune Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpine Immune Sciences
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Morphic
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Alpine Immune Sciences beats Morphic on 10 of the 18 factors compared between the two stocks.


Get Morphic News Delivered to You Automatically

Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MORF vs. The Competition

MetricMorphicPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.91B$6.44B$5.00B$7.50B
Dividend YieldN/A2.78%2.84%3.87%
P/E Ratio-10.9318.43266.8118.54
Price / Sales3,664.90185.683,363.93160.05
Price / CashN/A18.3325.7325.78
Price / Book2.725.524.694.64
Net Income-$152.10M$112.37M$112.29M$210.98M
7 Day Performance6.24%6.24%5.06%2.08%
1 Month Performance26.15%14.01%13.34%5.39%
1 Year Performance-8.23%5.89%13.38%8.57%

Morphic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALPN
Alpine Immune Sciences
1.0543 of 5 stars
$30.51
-2.4%
$29.00
-4.9%
+356.6%$1.77B$30.80M-25.43126Positive News
AMRX
Amneal Pharmaceuticals
1.4565 of 5 stars
$5.78
-2.0%
$5.40
-6.6%
+167.0%$1.77B$2.21B96.337,600Upcoming Earnings
News Coverage
KROS
Keros Therapeutics
1.6028 of 5 stars
$60.77
+2.2%
$84.20
+38.6%
+24.2%$1.82B$20.10M-12.28129Upcoming Earnings
NAMS
NewAmsterdam Pharma
2.6964 of 5 stars
$21.12
+1.9%
$28.50
+34.9%
+61.3%$1.72B$13.56M0.0022
ZLAB
Zai Lab
2.8614 of 5 stars
$19.24
-6.8%
$74.56
+287.5%
-41.0%$1.90B$215.04M-6.172,036News Coverage
Gap Up
HRMY
Harmony Biosciences
4.0593 of 5 stars
$33.02
-2.3%
$44.50
+34.8%
-28.4%$1.93B$437.86M13.42200Earnings Report
Analyst Report
SNDX
Syndax Pharmaceuticals
3.1659 of 5 stars
$22.87
+1.8%
$34.75
+51.9%
+1.6%$1.94B$139.71M-8.86107News Coverage
CPRX
Catalyst Pharmaceuticals
4.9464 of 5 stars
$13.79
-1.5%
$25.80
+87.1%
-7.1%$1.62B$214.20M26.5282Upcoming Earnings
News Coverage
PTCT
PTC Therapeutics
2.3428 of 5 stars
$25.98
+0.3%
$34.29
+32.0%
-35.4%$1.96B$698.80M-3.001,410Upcoming Earnings
News Coverage
Positive News
DVAX
Dynavax Technologies
4.5402 of 5 stars
$12.28
-1.0%
$25.00
+103.6%
+26.8%$1.60B$361.18M31.49351Analyst Revision

Related Companies and Tools

This page (NASDAQ:MORF) was last updated on 2/27/2024 by MarketBeat.com Staff